Latest Market Research News

X2M Connect reports improved revenue trends and a strengthened balance sheet after securing $5.5 million in new contracts, positioning the company for growth in FY26. A recent capital raise aims to reduce debt and fund expansion in key markets.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

OFX Limited reported a resilient FY25 with steady revenue and strong cash flow, while advancing its New Client Platform and strategic market expansion despite economic headwinds.

Metal Powder Works has secured a strategic contract with Westinghouse Electric Company to supply metal powders for additive manufacturing in nuclear applications, marking a key step in its growth trajectory.

Global Masters Fund Limited has appointed long-serving director Jason Pohl as its new Managing Director, signaling continuity in leadership and strategic focus.

Pureprofile Limited has reported a robust Q3 FY25 with revenue up 16% and EBITDA up 16% year-on-year, driving a 20% increase in year-to-date revenue and a 35% jump in EBITDA. The company’s international expansion and new AI-driven solutions underpin its confident outlook for FY25.

Industrial Minerals Ltd has reported promising progress in its high purity quartz beneficiation and ore-sorting trials at the Pippingarra Pegmatite Project, with growing interest from Asian markets and potential new co-products enhancing project economics.

Range International reported a 51% revenue increase in Q1 2025 despite supply chain disruptions that dented cash flow. The company is advancing growth initiatives including pallet rentals in Indonesia and expanding production to the Philippines.

Alpha HPA has responded to ASX inquiries confirming the material market sensitivity of its signed Letter of Intent (LOI) and related surge in semiconductor sector sales, underscoring the strategic importance of its high purity materials.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.